Drug Report History #280448
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that have changed between versions will be highlighted in yellow, and the changes will be clearly marked as updated.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow, and the change will be clearly marked as updated.
| Field | Version v2-FR | Version v2-FR |
|---|---|---|
| Language | French | French |
| Date Updated | 2026-03-12 | 2026-03-12 |
| Drug Identification Number | 00428833 | 00428833 |
| Brand name | YF-VAX | YF-VAX |
| Common or Proper name | Yellow Fever Vaccine | Yellow Fever Vaccine |
| Company Name | SANOFI VACCINES CANADA LTD. | SANOFI VACCINES CANADA LTD. |
| Ingredients | YELLOW FEVER VACCINE | YELLOW FEVER VACCINE |
| Strength(s) | 109648PFU | 109648PFU |
| Dosage form(s) | POWDER FOR SOLUTION | POWDER FOR SOLUTION |
| Route of administration | SUBCUTANEOUS SUBCUTANEOUS | SUBCUTANEOUS SUBCUTANEOUS |
| Packaging size | 5 x 0.5 mL dose vials with diluent | 5 x 0.5 mL dose vials with diluent |
| Anatomical Therapeutical Chemical (ATC) code | J07BL | J07BL |
| Anatomical Therapeutical Chemical (ATC) description | VIRAL VACCINES | VIRAL VACCINES |
| Reason for shortage | Delay in shipping of the drug. | Delay in shipping of the drug. |
| Anticipated start date | ||
| Actual start date | 2026-03-09 | 2026-03-09 |
| Estimated end date | 2026-04-23 | 2026-04-23 |
| Actual end date | ||
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | YF-VAX supply is temporarily constrained due to a manufacturing delay, limiting available inventory only for the private market. Sanofi is working to resolve the situation as soon as possible. | YF-VAX supply is temporarily constrained due to a manufacturing delay, limiting available inventory only for the private market. Sanofi is working to resolve the situation as soon as possible. |
| Health Canada comments |